Vascular Endothelial Growth Factor as Potential Biomarker for COVID-19 Severity

Journal of Intensive Care Medicine, Journal Year: 2023, Volume and Issue: 38(12), P. 1165 - 1173

Published: July 13, 2023

Introduction COVID-19 is characterized by immunological responses to viral replication and coherent with endothelitis, microvascular disturbance of lung vasculature coagulopathy. Vascular Endothelial Growth Factor (VEGF) a proangiogenic mediator regulating endothelial changes. It induced proinflammatory signaling hypoxia. We sought determine whether VEGF levels differ between SARS-CoV-2-positive patients different disease severity might be useful in risk stratification. Methods After retrospective screening all treated Unfallkrankenhaus Berlin 2020, we included those documented measurement. extracted laboratory values clinical parameters. An exploratory data analysis was performed detect possible relations level features. Results 167 which 139 suffered from COVID-19. Seventy-one the had intensive care unit (ICU), exhibited higher than being admitted normal wards (535 vs 279 pg/L, P < .001). APACHE-2 (Acute Physiology And Chronic Health Evaluation Score) correlated mortality high showed concentrations on admission (456 875 p = 0.006). Receiver operating characteristic analytic revealed that occurrence organ dysfunctions like acute respiratory distress syndrome (ARDS), shock, or kidney injury could predicted VEGF. significantly who later died compared survivors (637 389 pg/mL, 0.041) same accuracy as established markers. In our cohort, association above 277 pg/L ARDS confirmed logistic regression adjusting for confounding factors (odds ratio 3.1, 95% confidence interval: 1.34-7.7). Discussion Even though there are several limitations this study it can contribute prediction necessity ICU, ARDS, shock. Its use stratification potential pathogenetic involvement should further investigated.

Language: Английский

---

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates

Nature Communications, Journal Year: 2022, Volume and Issue: 13(1)

Published: Aug. 30, 2022

Abstract The COVID-19 pandemic has exemplified that rigorous evaluation in large animal models is key for translation from promising vitro results to successful clinical implementation. Among the drugs have been largely tested trials but failed so far bring clear evidence of efficacy favipiravir, a nucleoside analogue with spectrum activity against several RNA viruses and small models. Here, we evaluate antiviral favipiravir Zika or SARS-CoV-2 virus cynomolgus macaques. In both models, high doses are initiated before infection viral kinetics evaluated during 7 15 days after infection. Favipiravir leads statistically significant reduction plasma load compared untreated animals. However, no effects on kinetics, 4 treated animals be euthanized due rapid deterioration, suggesting potential role disease worsening infected To summarize, an not macaque model. Our support they advocate its use

Language: Английский

---

Identification of common molecular signatures of SARS-CoV-2 infection and its influence on acute kidney injury and chronic kidney disease

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: March 21, 2023

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the main cause of COVID-19, causing hundreds millions confirmed cases and more than 18.2 million deaths worldwide. Acute kidney injury (AKI) a common complication COVID-19 that leads to an increase in mortality, especially intensive care unit (ICU) settings, chronic disease (CKD) high risk factor for its related mortality. However, underlying molecular mechanisms among AKI, CKD, are unclear. Therefore, transcriptome analysis was performed examine pathways biomarkers attempt understand association SARS-CoV-2 infection with AKI CKD. Three RNA-seq datasets (GSE147507, GSE1563, GSE66494) from GEO database were used detect differentially expressed genes (DEGs) CKD search shared candidate targets. A total 17 DEGs confirmed, their biological functions signaling characterized by enrichment analysis. MAPK signaling, structural pathway interleukin 1 (IL-1), Toll-like receptor appear be involved occurrence these diseases. Hub identified protein–protein interaction (PPI) network, including DUSP6, BHLHE40, RASGRP1, TAB2, potential therapeutic targets Common may play pathogenic roles three diseases mainly through activation immune inflammation. Networks transcription (TF)–gene, miRNA–gene, gene–disease interactions also constructed, key gene regulators influencing progression further DEGs. Moreover, new drug predicted based on DEGs, docking dynamics (MD) simulations performed. Finally, diagnostic model established Taken together, this study which affects renal function. These findings significant effective treatment patients

Language: Английский

---

COVID-19 and immune dysfunction: Consequences and natural remedies for management

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 235 - 264

Published: Jan. 1, 2025

Language: Английский

---

Incidence, pathophysiology, risk factors, histopathology, and outcomes of COVID-19-induced acute kidney injury: a narrative review

Microbial Pathogenesis, Journal Year: 2025, Volume and Issue: unknown, P. 107360 - 107360

Published: Jan. 1, 2025

Language: Английский

---

The Role of Viral Infections in Acute Kidney Injury and Mesenchymal Stem Cell-Based Therapy

Stem Cell Reviews and Reports, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

Language: Английский

---

IMPACTO DO BALANÇO HÍDRICO NA MORTALIDADE DE PACIENTES HOSPITALIZADOS COM COVID-19 E INJÚRIA RENAL AGUDA GRAVE

Revista Foco, Journal Year: 2025, Volume and Issue: 18(4), P. e8274 - e8274

Published: April 16, 2025

Introdução: O BHA é identificado como variável independente para mortalidade em pacientes com IRA. Não há estudos que avaliaram a relação entre sobrecarga de fluidos e na população COVID-19 IRA graves. Objetivos: Investigar associação dos COVID 19 KDIGO3. Metodologia: Estudo coorte retrospectivo, incluídos evoluíram grave UTIs do hospital referência abril/2020 Dez/2021. A função renal o diagnóstico realizado acordo KDIGO 2012. foi calculado através da subtração ganhos – perdas líquido paciente. Utilizado Teste Qui-Quadrado (categóricas) t (contínuas), distribuição normalidade. Análise regressão logística, cálculos Odds Ratio, p≤0,05. Resultados: 196 pacientes, maioria homens (59,7%), idade 61±14 anos, 96,7% UTI, 69% hipertensos, 46,4% obesos 36,3% diabéticos, positivo 88,7% geral 85,2%. Em ao óbito, os grupos diferiram quanto à (61,9±14,1 vs 55,5±13,1 anos naqueles alta; p=0,02); tempo internação (16±13,4 48,8±23,5 dias (p<0,001) VM (14,4±13,2 26,28±10,97 dias, p<0,001), APACHE (21,9 ± 7,94 15,1 7,1, p<0,001) (88,0% 68,9%, p=0,019). Regressão logística identificou fatores associados óbito (OR 4,2, IC 1,008-17,99, p=0,05) VM, 0,931, 0,89-0,97, p=0,002). Conclusão: teve impacto significativo no desfecho óbito.

---

New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: June 7, 2024

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the distress condition known as COVID-19. This disease broadly affects several physiological systems, including gastrointestinal, renal, and central nervous (CNS) significantly influencing patient’s overall quality of life. Additionally, numerous risk factors have been suggested, gender, body weight, age, metabolic status, renal health, preexisting cardiomyopathies, inflammatory conditions. Despite advances in understanding genome pathophysiological ramifications COVID-19, its precise origins remain elusive. SARS-CoV-2 interacts with a receptor-binding domain within angiotensin-converting enzyme (ACE2). receptor expressed various organs different species, humans, abundance. Although COVID-19 has multiorgan manifestations, main pathologies occur lung, pulmonary fibrosis, failure, embolism, secondary bacterial pneumonia. In post-COVID-19 period, sequelae may occur, which causes, direct action virus, alteration immune response, alterations during infection, among others. Recognizing serious adverse health effects associated it becomes imperative to comprehensively elucidate discuss existing evidence surrounding this viral those related subsequent consequences. review aims contribute comprehensive impact long-term on human health.

Language: Английский

---

Renal pathology in severe COVID-19

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 311 - 318

Published: Jan. 1, 2025

Language: Английский

---

Bridging Cancer and COVID‐19: The Complex Interplay of ACE2 and TMPRSS2

Cancer Medicine, Journal Year: 2025, Volume and Issue: 14(7)

Published: March 27, 2025

ABSTRACT The coronavirus disease 2019 (COVID‐19) pandemic presents heightened risks for cancer patients, who are more susceptible to severe acute respiratory syndrome 2 (SARS‐CoV‐2) infection and outcomes due immunosuppression from both the malignancy anticancer therapies. This review investigates dual roles of angiotensin‐converting enzyme (ACE2) transmembrane serine protease (TMPRSS2) in SARS‐CoV‐2 among patients. ACE2, vital entry receptor SARS‐CoV‐2, is overexpressed certain tumors such as colon adenocarcinoma, renal carcinomas, pancreatic lung potentially increasing viral susceptibility. Paradoxically, ACE2 also exhibits tumor‐suppressive properties by inhibiting angiogenesis modulating tumor microenvironment, leading improved patient prognoses some cancers like breast cancer. TMPRSS2, essential entry, shows decreased expression several but acts a prognostic biomarker prostate cancers. illustrates complexity therapeutically targeting TMPRSS2 their contrasting progression entry. We analyze levels relation immune cell infiltration outcomes, propose personalized therapeutic strategies. Furthermore, we underscore necessity multidisciplinary approaches, integrating antiviral treatments with therapies tailoring interventions based on individual molecular profiles. approach medicine seeks enhance treatment results better manage patients have contracted SARS‐CoV‐2.

Language: Английский

---